News Releases

ACZONE® (dapsone) GEL, 7.5% Now Approved For The Topical Treatment Of Acne Vulgaris In Patients 9 Years Of Age And Older
Almirall issues call for grant submissions for development of new immunodermatology therapies through AlmirallShare
Almirall Partners with AARS to Raise Awareness about the Burden of Disease and Importance of Education for Dermatology Professionals for National Acne Awareness Month
Almirall Q1 2019. Strong operating performance
Almirall Recognized As Distinguished Corporate Leader By American Skin Association - Unveiled Patient-Driven Purpose
Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
Almirall enters into a definitive agreement to divest ThermiGen, its medical device aesthetics business
Novel Oral Antibiotic SEYSARA™ (sarecycline) Now Available
Almirall LLC Launches New Name at Fall Clinical Dermatology Congress
Almirall acquires Allergan U.S. medical dermatology portfolio

Media Inquiries
Sam Widdicombe
Senior Director, Strategic Communications
media.us@almirall.com

Almirall PR
almirallpr.us@almirall.com